acamprosate vs paliperidone
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and paliperidone. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Invega
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Paliperidone extended-release tablets, also known as Invega, are a type of antipsychotic medicine. It helps manage symptoms of certain mental disorders.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
This medicine is used to treat schizophrenia in adults and teens (12-17 years old). It can also treat schizoaffective disorder in adults, either alone or with other medicines like mood stabilizers or antidepressants. Schizophrenia can cause hallucinations, delusions, and confused thinking. Schizoaffective disorder includes symptoms of both schizophrenia and mood disorders.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Paliperidone affects certain chemicals in the brain. These chemicals, like dopamine, can become unbalanced in people with schizophrenia and schizoaffective disorder. By acting on these chemicals, paliperidone helps to reduce symptoms.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Extrapyramidal symptoms (movement problems)
- • Fast heart rate
- • Feeling restless and unable to sit still
- • Sleepiness
- • Indigestion
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Injury 4,331
- Gynaecomastia 3,664
- Abnormal Weight Gain 1,660
- Weight Increased 1,361
- Hyperprolactinaemia 1,255
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
This medicine has a boxed warning. It may increase the risk of death in elderly patients with dementia-related psychosis. Paliperidone is not approved to treat this condition.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
If you are pregnant or plan to become pregnant, talk to your doctor. Babies born to mothers who use this medicine in the last 3 months of pregnancy may have withdrawal symptoms or movement problems after birth. There is a pregnancy registry to monitor outcomes in women exposed to atypical antipsychotics during pregnancy. You can contact the registry at 1-866-961-2388.
Also Compare, Nearby Drugs
Compare paliperidone with
How to Read This acamprosate vs paliperidone Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while paliperidone sits within the Atypical Antipsychotic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while paliperidone has 12,271. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or paliperidone.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.